HK1023064A1 - Method of inhibiting bacterial or fungal growth using a complexing agent - Google Patents

Method of inhibiting bacterial or fungal growth using a complexing agent

Info

Publication number
HK1023064A1
HK1023064A1 HK00102166A HK00102166A HK1023064A1 HK 1023064 A1 HK1023064 A1 HK 1023064A1 HK 00102166 A HK00102166 A HK 00102166A HK 00102166 A HK00102166 A HK 00102166A HK 1023064 A1 HK1023064 A1 HK 1023064A1
Authority
HK
Hong Kong
Prior art keywords
complexing agent
fungal growth
inhibiting bacterial
solution
bacterial
Prior art date
Application number
HK00102166A
Other languages
English (en)
Inventor
Harry S Winchell
Joseph Y Klein
Elliot D Simhon
Rosa L Cyjon
Ofer Klein
Haim Zaklad
Original Assignee
Chelator Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chelator Llc filed Critical Chelator Llc
Publication of HK1023064A1 publication Critical patent/HK1023064A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK00102166A 1995-06-26 2000-04-10 Method of inhibiting bacterial or fungal growth using a complexing agent HK1023064A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52495P 1995-06-26 1995-06-26
US56062695A 1995-11-20 1995-11-20

Publications (1)

Publication Number Publication Date
HK1023064A1 true HK1023064A1 (en) 2000-09-01

Family

ID=26667775

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00102166A HK1023064A1 (en) 1995-06-26 2000-04-10 Method of inhibiting bacterial or fungal growth using a complexing agent

Country Status (10)

Country Link
US (4) US5874573A (ja)
EP (3) EP0955044B1 (ja)
JP (4) JP3356289B2 (ja)
CN (1) CN1203899C (ja)
AT (1) ATE309794T1 (ja)
AU (1) AU703340B2 (ja)
CA (1) CA2225453C (ja)
DE (1) DE69635460T2 (ja)
HK (1) HK1023064A1 (ja)
WO (1) WO1997001360A2 (ja)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
JP3356289B2 (ja) * 1995-06-26 2002-12-16 コンキャット リミティド 第一遷移系列元素に対してキレート化親和性および選択性のある化合物とその医療および診断への使用
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
CA2309749A1 (en) 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
DE19809542A1 (de) * 1998-03-05 1999-09-09 Clariant Gmbh Quaternäre polycyclische Polyammoniumsalze und Verfahren zu deren Herstellung
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
AU770999C (en) 1999-10-01 2005-04-21 Ampio Pharmaceuticals, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
AU2001256155A1 (en) * 2000-02-29 2001-09-12 Unilever Plc Composition and method for bleaching a substrate
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
AU2000251520A1 (en) * 2000-05-19 2001-12-03 Bio-Defense Nutritionals Antiviral methods and compositions
WO2002006287A2 (en) * 2000-07-17 2002-01-24 California Institute Of Technology Macrocyclic mri contrast agents
AU2001292792A1 (en) * 2000-09-25 2002-04-08 The Procter And Gamble Company Manganes complexes for magnetic resonance imaging
CA2420645A1 (en) * 2000-09-25 2002-04-04 The Procter & Gamble Company Metal complexes for use in medical and therapeutic applications
AU2002211393B2 (en) * 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
JP4683249B2 (ja) * 2000-10-27 2011-05-18 Ｄｉｃ株式会社 ポリフェノ−ル化合物とその製造方法
US6576760B2 (en) 2001-01-11 2003-06-10 Chelator Llc Processes for synthesis of cyclic and linear polyamine chelators containing N-monosubstituted coordinating arms
JP4397540B2 (ja) * 2001-03-16 2010-01-13 日本メジフィジックス株式会社 癌の骨転移治療法選択のための画像診断用薬剤
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US6881732B2 (en) * 2002-06-13 2005-04-19 Chelator Llc Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
ES2411961T5 (es) 2002-11-01 2017-04-27 Rutgers, The State University Of New Jersey Vehículos de suministro en forma de geoda
WO2004062674A2 (en) * 2003-01-07 2004-07-29 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
WO2004100884A2 (en) * 2003-05-07 2004-11-25 Dmi Biosciences, Inc. Oral care methods and products
US20050112066A1 (en) * 2003-11-26 2005-05-26 Concat Lp, A California Limited Partnership Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
ATE552833T1 (de) * 2006-02-14 2012-04-15 Eastern Virginia Med School Methoxypolyethylenglykol-thioester-chelat und dessen verwendung
RU2506256C2 (ru) 2006-12-26 2014-02-10 Лантеус Медикал Имэджинг, Инк. Лиганды для визуализации иннервации сердца
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
EP1985312A1 (en) * 2007-04-25 2008-10-29 Koninklijke Philips Electronics N.V. T1 reduction in 19F magnetic resonance imaging (MRI)
JP2008303168A (ja) * 2007-06-07 2008-12-18 Japan Health Science Foundation 破骨細胞制御剤とそのスクリーニング方法
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
WO2009029727A1 (en) * 2007-08-28 2009-03-05 Vanderbilt University Cannabinoid receptor targeted agent
CA2711426C (en) 2008-01-08 2018-05-22 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
US10556873B2 (en) * 2008-02-22 2020-02-11 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
WO2009113148A1 (ja) * 2008-03-10 2009-09-17 Dic株式会社 鉄錯体を触媒とする重合体の製造方法
WO2012082618A2 (en) * 2010-12-13 2012-06-21 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
EP2206506A1 (en) 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotic formulations
EP2451776B1 (en) 2009-07-08 2019-09-18 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
EP2569019B1 (en) 2010-05-11 2019-10-02 Lantheus Medical Imaging, Inc. Compositions, methods and systems for the synthesis and use of imaging agents
JP6124078B2 (ja) * 2010-08-26 2017-05-10 ツイ，クンユァン 巨大環状脂肪族化合物及びその応用
WO2012151554A1 (en) * 2011-05-04 2012-11-08 President And Fellows Of Harvard College Polyamines for treating biofilms
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
US9034927B2 (en) 2013-05-22 2015-05-19 Curza Global, Llc Methods of use for compositions comprising a biocidal polyamine
US9439433B2 (en) 2013-05-22 2016-09-13 Curza Global, Llc Compositions and methods comprising a biocidal polyamine
EP2871186B1 (en) * 2013-11-12 2016-09-21 Université de Bretagne Occidentale Picolinate cross-bridged cyclams, chelates with metallic cations and use thereof
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
CN104892533B (zh) * 2015-05-11 2017-03-29 陕西师范大学 Tb(III)配合物及其制备方法和在检测杀螟腈中的应用
KR101709124B1 (ko) * 2015-08-19 2017-02-22 기초과학연구원 신규한 키랄 금속 착물 및 분광법에 의해 전하를 띤 화합물의 키랄성을 분석하기 위한 이의 용도
CN110785082B (zh) 2017-04-05 2021-12-28 库扎环球有限责任公司 包含三芳基聚胺的组合物和方法
KR20210114932A (ko) * 2018-11-16 2021-09-24 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 음이온 펜던트 및 보조기를 함유하는 철 (iii) mri 조영제로 사용하기 위한 화합물
EP4308550A1 (en) * 2021-03-19 2024-01-24 The Hong Kong Polytechnic University Chiral tacn/nota compounds/derivatives with and without metals for application

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT325023B (de) * 1935-11-15 1975-09-25 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen racemischen oder optisch aktiven n,n'- bis - (3 - subst. phenoxy -2- hydroxy -1- propyl) - alfa, omega - diaminoalkanen sowie deren säureadditionssalzen
DE2260444A1 (de) * 1972-12-11 1974-06-12 Boehringer Sohn Ingelheim Neue bis-alkanol-aminderivate, deren saeureadditionssalze, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR1253855A (fr) * 1959-12-22 1961-02-17 Shell Int Research Procédé de préparation des acides carboxyliques par la réaction de composés nonsaturés oléfiniquement, avec de l'eau et de l'oxyde de carbone
GB923311A (en) * 1960-09-14 1963-04-10 Ici Ltd Pharmaceutical anti-mycobacterial compositions comprising ethylenediamine derivatives
GB919177A (en) * 1960-09-14 1963-02-20 Ici Ltd Substituted ethylenediamines
FR2098M (fr) * 1962-10-25 1963-10-21 S Des Laboratoires Robert Et C Médicament dérivé la pipérazine.
US3271383A (en) * 1963-06-11 1966-09-06 Mitsubishi Chem Ind Disazo dyes containing an nu-substituted benzothiazolyl group
US3432547A (en) * 1963-08-21 1969-03-11 Armour & Co Bis-aminophosphinic acids useful as anti-bacterial agents
US3398196A (en) * 1964-12-31 1968-08-20 Armour Ind Chem Co Nu-secondary-alkyl trimethylene diamines
US3741973A (en) * 1967-09-11 1973-06-26 Upjohn Co Oxygenated 3-azabicyclo(3.3.1)nonanes
US3524854A (en) * 1968-04-16 1970-08-18 Dow Chemical Co Hexamethylenetetramine salts of cyanoalkyl halides
DE1901549B2 (de) * 1968-09-30 1978-04-13 Veb Fahlberg-List, Chemische Und Pharmazeutische Fabriken, Ddr 3011 Magdeburg N,N'-Bis-[3-(2'-äthoxyphenoxy)-2-hydroxypropyl] -ethylendiamin, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis
JPS5210847B1 (ja) * 1969-12-30 1977-03-26
CH534480A (de) * 1970-02-27 1973-03-15 Goldschmidt Ag Th Verwendung von Verbindungen als Biocide
DE2113208C3 (de) * 1971-03-18 1974-04-25 Th. Goldschmidt Ag, 4300 Essen Octylaminderivate, deren Herstellung und Verwendung als Bioeide
BE806413A (fr) * 1972-12-20 1974-02-15 Goldschmidt Ag Th Melange a action microbicide et son procede de preparation
DE2300543A1 (de) * 1973-01-08 1974-07-11 Basf Ag 6700 Ludwigshafen Neue derivate des trimethylphenols und verfahren zu ihrer herstellung
US4022833A (en) * 1973-02-14 1977-05-10 Sterling Drug Inc. N,N'-bridged-bis[2-alkyl-2-hydroxyethylamines]
NL7505669A (nl) * 1974-05-16 1975-11-18 Oreal Gequaterniseerde polymeren en werkwijze ter bereiding hiervan.
US3906105A (en) * 1974-06-10 1975-09-16 Nalco Chemical Co Cyanoethyl and haloethyl diamines as bactericides and fungicides
US3956502A (en) * 1974-09-04 1976-05-11 Nalco Chemical Company Polyamine alcohols as microbiocides
IT1052432B (it) * 1974-12-04 1981-06-20 Goldschmidt Ag Th Derivati n.alchilici alcossilati della propilendiammina e preparati che li contengono
FR2341314A1 (fr) * 1976-02-19 1977-09-16 Goupil Jean Jacques Halogenohydrates de derives n,n'-di substitues de la piperazine
US4072741A (en) * 1976-12-17 1978-02-07 Imc Chemical Group, Inc. Method of controlling the growth of bacteria and fungi using N-hydroxymethylalkylene diamines
US4515766A (en) * 1980-06-23 1985-05-07 The Massachusetts General Hospital Labeled phosphonic acid compositions for investigations of in vivo deposits of calcium
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
JPS5925692A (ja) * 1982-08-03 1984-02-09 Mitsubishi Chem Ind Ltd ポリアミン
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
FR2557101B1 (fr) * 1983-12-21 1986-06-27 Pharmascience Lab Nouveau procede de preparation de diamine-alcools
JPS60202869A (ja) * 1984-03-26 1985-10-14 Ajinomoto Co Inc 大環状ポリアミン誘導体及びその用途
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US4749560A (en) * 1984-08-13 1988-06-07 Research Corporation Metal organo phosphorous compounds for NMR analysis
US5342606A (en) * 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
CA1317937C (en) * 1984-10-18 1993-05-18 A. Dean Sherry Gadolinium chelates with carboxymethyl derivatives of polyazamacrocycles as nmr contrast agents
GB8518300D0 (en) * 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
AU608759B2 (en) * 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
GB8701054D0 (en) * 1987-01-16 1987-02-18 Amersham Int Plc Contrast agent for nmr scanning
AU602186B2 (en) * 1987-02-03 1990-10-04 Merrell Dow Pharmaceuticals Inc. Novel polyamine derivatives
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
EP0309980A1 (en) * 1987-10-02 1989-04-05 The B.F. Goodrich Company Alkylated polyalkylene polyamines and process for selective alkylation
ZA887410B (en) * 1987-10-08 1989-06-28 Merrell Dow Pharma Polyamine derivatives as antineoplastic agents
NZ229700A (en) * 1988-06-24 1993-01-27 Dow Chemical Co Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments
GB8903023D0 (en) * 1989-02-10 1989-03-30 Parker David Chemical compounds
JPH03504510A (ja) * 1989-02-10 1991-10-03 セルテック　リミテッド アザマクロサイクルおよびその製法
IL89349A0 (en) * 1989-02-20 1989-09-10 Hadassah Medical Organisation Pharmaceutical composition for protecting the heart comprising a heterocyclic ethylenediamine derivative and methods for the use thereof
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
GB8914543D0 (en) * 1989-06-23 1989-08-09 Parker David Chemical compounds
DE3930674A1 (de) * 1989-09-11 1991-03-21 Diagnostikforschung Inst Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
DE4009119A1 (de) * 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
JPH05500969A (ja) * 1990-04-18 1993-02-25 セルテック　リミテッド テトラ―アザ大環状化合物、それらの調製法およびそれらの磁気共鳴画像形成での使用
GB9211291D0 (en) * 1992-05-28 1992-07-15 British Tech Group Antifungal compounds
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5409689A (en) * 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
WO1996030377A1 (en) * 1995-03-27 1996-10-03 Isis Pharmaceuticals, Inc. Nitrogenous macrocyclic compounds
US5663161A (en) * 1995-02-17 1997-09-02 The Research Foundation Of State University Of New York Anti-viral triaza compounds
JP3356289B2 (ja) * 1995-06-26 2002-12-16 コンキャット リミティド 第一遷移系列元素に対してキレート化親和性および選択性のある化合物とその医療および診断への使用
GB0001129D0 (en) 2000-01-18 2000-03-08 Unilever Plc Anti-microbial aerosol compositions
ATE357275T1 (de) 2000-01-18 2007-04-15 Unilever Nv Antimikrobielle schweisshemmende produkte
ATE369112T1 (de) 2000-01-18 2007-08-15 Unilever Nv Antimikrobielle zubereitung salz eines übergangmetall-chelators enthaltend
GB0024689D0 (en) 2000-10-09 2000-11-22 Unilever Plc Deodorant products

Also Published As

Publication number Publication date
JP2001316253A (ja) 2001-11-13
EP1382332A1 (en) 2004-01-21
JP2002012582A (ja) 2002-01-15
ATE309794T1 (de) 2005-12-15
EP0955044B1 (en) 2005-11-16
US6583182B1 (en) 2003-06-24
WO1997001360A3 (en) 1997-03-13
US6165996A (en) 2000-12-26
CA2225453C (en) 2004-12-14
WO1997001360A2 (en) 1997-01-16
EP0955044A3 (en) 2000-03-08
JP2002003408A (ja) 2002-01-09
CA2225453A1 (en) 1997-01-16
EP0841951A2 (en) 1998-05-20
CN1189105A (zh) 1998-07-29
AU6635596A (en) 1997-01-30
US5874573A (en) 1999-02-23
CN1203899C (zh) 2005-06-01
AU703340B2 (en) 1999-03-25
DE69635460T2 (de) 2006-08-10
JP3356289B2 (ja) 2002-12-16
EP0955044A2 (en) 1999-11-10
US6469162B1 (en) 2002-10-22
DE69635460D1 (de) 2005-12-22
JPH10512584A (ja) 1998-12-02

Similar Documents

Publication Publication Date Title
HK1023064A1 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
GEP20032897B (en) Epothilone Derivatives
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
AU1015095A (en) Method of treating hyperproliferative vascular disease
IL104154A0 (en) Saccharin derivatives,their preparation and pharmaceutical compositions containing them
IL108846A0 (en) Use of lamortrigine in the treatment of neuro aids
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
AU697679B2 (en) Treatment of tinnitis using neuroprotective agents
BG103947A (en) Derivatives of 9-oxymerythromycin
IN2012DE00109A (ja)
GEP20032953B (en) Antitumor Agents
WO1999051256A3 (en) Use of l-glu-l-trp in the treatment of hiv infection
MY132057A (en) Quinoxalinones, a process for their preparation and their use
TW327171B (en) 2-heteroaryl-5 for prevention or treatment of HIV infection
EP1152762B8 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
AU4630599A (en) Perfume composition
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
ATE211489T1 (de) Chitosan enthaltende zusammensetzung
MY132436A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
AU5434899A (en) Cancer treatment
ZA981558B (en) Inclusion complexes in aqueous solution
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
MY130771A (en) 3-azabicyclo [3.1.0] hexane derivatives useful in therapy.
EP0412941A3 (en) Phospholipids for the treatment of multiple sclerosis
BG102974A (en) Ethene-containing solutions and their use in methods of treatment or prevention

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090624